更多资料加入知识星球：水木调研纪要 关注公众号：水木Alpha 4 June 2025 | 8:12PM HKT Li Ning Co. (2331.HK): Consumer & Leisure Corporate Day: 2025 outlook reiterated though discount is key to watch; Neutral Bottom line: We hosted Li Ning at our Consumer & Leisure Corporate Day on Jun 4 and mgmt reiterated FY2025 guidance and highlighted YTD trading and OPEX investment (incl COC sponsorship)/non-OP are largely on track, but GPM could see uncertainties due to promotions/discount. More specifically, 1) Recent trend: With stable consumer ...

Group 1 - Investors often face a choice between momentum and value, which can also lead to a conflict between fundamentals and value [1] - When a company or sector performs exceptionally well, the stock market tends to become overly enthusiastic [1] Group 2 - The company invests significant resources, including thousands of hours and over $100,000 annually, into researching profitable investment opportunities [2] - The approach has garnered over 180 five-star reviews from satisfied members, indicating a positive reception and effectiveness [2]

Key Takeaways BCS is restructuring through divestitures and redeploying capital into high-growth core businesses. Cost-saving moves like asset sales and division changes yielded 1.15 billion euros in savings through Q1 2025. BCS aims for 2 billion euros in gross efficiency savings by 2026 and a cost-to-income ratio in the high 50s.Barclays PLC (BCS) has been taking steps to divest unprofitable/less profitable operations and save expenses through business streamlining, while deploying the capital into high ...

One of the strangest earnings seasons is almost over. We paid more attention to geopolitical news and its consequences on the listed companies' guidance rather than focusing on the reports themselves and what the numbers showed. After all, we are all asking ourselvesI focus on long term growth and dividend growth investing. I follow both the US and the European stock markets, looking for undervalued stock and/or for high quality dividend growing companies that provide me with cash to reinvest. Over time, I ...

"中国汽车产业的恒大已经存在"。近日，长城汽车董事长魏建军的一番发言，在汽车圈激起了千层浪，矛头直指近两年车圈的价格战。 魏建军在接受访问中指出，纯电动车亏损严重，难以形成商业闭环，这是如今的产业困境。他直言，"什么样的工业产品能降10万元还得到质量保证？" 事实上，魏建军近年已经不止一次呼吁"反内卷"，他认为过度的价格竞争只会导致恶性循环，对于企业正常的发展而言，必须有合理的利润。 在商业世界里，没有一家企业不是奔着"盈利"的目标入场的。但过去两年，已有数十家车企倒下，市场竞争愈发激烈，"价格战"成为了车企们无奈却又不 得不选择的"武器"，试图通过降价来抢占有限的市场份额，缓解库存压力。 只不过，当人人都拾起"低价武器"，与其喊话让市场"停一停，等一等"，当下如何跟上市场节奏，反而才是车企当下最着急的命题。 1 立下盈利军令状 苦于车圈价格战的，并不只有魏建军一位。近日，小鹏汽车董事长何小鹏也谈到了价格战，他表示目前车市的竞争还不算激烈，在下一个5年中的某一年 竞争会更激烈，只是单纯卷价格的能力不足以支撑（企业）发展，应该要卷科技，走出国门。 2023年，小鹏曾一度躺进"ICU"，此后便开始积极调整经营战略 ...

Key Takeaways BROS' Q1 2025 shop margin fell 40 bps to 29.4% amid rising labor, coffee tariffs and opening costs. The company expects 110 bps of full-year COGS margin pressure despite fixed coffee prices and cost controls. BROS is boosting digital efforts while aiming for 2,029 stores by 2029, despite short-term margin strain.Dutch Bros Inc. (BROS) continues to benefit from robust revenue growth and store expansion efforts. However, rising costs continue to challenge its path to higher profitability.In th ...

Summary of Quidel Ortho Conference Call Company Overview - Quidel Ortho was formed by the merger of Quidel and Ortho Clinical Diagnostics in May 2022, focusing on four major business areas: labs, transfusion medicine, point of care, and molecular diagnostics [5][6] - The company reported approximately $2.8 billion in revenue for the full year 2024, with North America contributing 58% of total revenues [6][7] Market Position and Growth Opportunities - The in vitro diagnostics market is valued at $50 billion, growing in the mid-single digits, with Quidel Ortho targeting segments worth approximately $20 billion [9] - The labs business generated $1.4 billion in revenue in 2024, representing about 50% of total revenue, and is expected to grow consistently [10] - The transfusion medicine business, excluding donor screening, generated $523 million in revenue in 2024, with low single-digit growth expected [12] - Point of care contributed $694 million in revenue in 2024, with mid-single-digit growth anticipated [13] - Molecular diagnostics revenue was $24 million in 2024, identified as a significant near-term growth opportunity [13] Strategic Initiatives - The company announced plans to acquire full ownership of Lex Diagnostics for approximately $100 million, aiming to enhance its product portfolio [14][15] - Discontinuation of the Savanna platform was decided due to unsatisfactory clinical trial results, allowing a focus on more promising technologies [15] - The Lex platform is expected to provide rapid and accurate testing, integrating well into existing workflows [16][17] Financial Performance and Cost Management - In Q1, Quidel Ortho achieved a 6% revenue growth, excluding COVID and donor screening, with a 450 basis point improvement in adjusted EBITDA [23] - Cost savings of over $100 million were identified in 2024, with an additional $30 million to $50 million expected in 2025 [22] - The company aims to reduce its net leverage ratio to 2.5 to 3.5 times while expanding margins [24][25] Future Outlook - The company reaffirmed its 2025 financial guidance, targeting mid to high 20s adjusted EBITDA margin [25] - Capital allocation will prioritize business needs, including menu expansion and molecular strategy, while focusing on cash generation and debt reduction [26] - Quidel Ortho is positioned for profitable growth with a strong value proposition and stable underlying business [27]

Dollar Tree Inc. DLTR stock is trading lower during the premarket after its first-quarter 2025 earnings report. 6.4% consumables comp and 4.6% discretionary comp – highest discretionary comp growth since Q4 2022. Net sales increased 11.3% to $4.6 billion, beating the consensus of $4.53 billion and the management guidance of $4.5 billion—$4.6 billion. On Wednesday, Dollar Tree reported adjusted earnings of $1.26 per share, beating the analyst estimate of $1.21, better than management expectation of $1.10 – $ ...

Core Viewpoint - Karolinska Development AB's portfolio company OssDsign successfully completed a directed share issue, raising approximately SEK 158 million, and announced an updated strategy and revised financial targets for 2025–2028 [1][3]. Group 1: Directed Share Issue - OssDsign's directed share issue attracted both existing and new institutional investors, including Adrigo Asset Management and La financiere de L'Echiquier, with the subscription price determined through an accelerated bookbuilding procedure [2][3]. - The successful share issue is expected to strengthen OssDsign's efforts in accelerating sales growth and building a long-term profitable business [3]. Group 2: Updated Strategy and Financial Targets - The new strategy, "ScaleToProfit," focuses on investments in four main areas: sales and marketing, research and development, clinical studies, and production [3][8]. - Revised financial targets include achieving sales of over SEK 400 million by 2028, which represents a compounded annual growth rate of over 30% during 2025–2028, and becoming EBIT profitable and cash flow positive in the second half of 2025–2028 [8]. Group 3: Company Overview - Karolinska Development holds a 3% ownership stake in OssDsign [4]. - The company is a Nordic life sciences investment firm that identifies and invests in breakthrough medical innovations, aiming to create and grow companies that advance these innovations into commercial products [5][6]. - Karolinska Development has a portfolio of eleven companies targeting innovative treatments for serious diseases [7].

Core Insights - The Zacks Transportation - Airline industry is facing challenges such as economic uncertainties, supply chain issues, high labor costs, and aircraft shortages, leading to a reduction in IATA's traffic and profit forecasts for 2025 [1][11]. Industry Forecast - IATA now projects a net profit of $36 billion for the airline industry in 2025, slightly down from the previous estimate of $36.6 billion, but still higher than the 2024 net profit of $32.4 billion [3][11]. - Total revenues are expected to reach $979 billion in 2025, with passenger revenues projected at a record $693 billion, which is 1.3% higher than 2024 but below the earlier forecast of $1 trillion [4][11]. - The number of passengers is expected to be 4.99 billion in 2025, a 4% increase from 2024, but lower than the previous estimate of 5.22 billion [4]. Revenue Breakdown - Passenger revenues are the primary driver for the 2025 projections, anticipated to be $693 billion, which is 1.6% above 2024 levels [5]. - Ancillary revenues are expected to increase by 6.7% compared to 2024 [5]. - Cargo revenues are projected to decline to $147 billion, a 4.7% year-over-year decrease, due to reduced GDP growth and lower demand [6]. Cost Projections - Total costs for 2025 are projected at $913 billion, which is 1% higher than 2024 but lower than the previous forecast of $940 billion, mainly due to reduced fuel costs [7]. - The average jet fuel cost is expected to decrease to $86 per barrel in 2025 from $99 per barrel in 2024, leading to a total fuel bill of $236 billion [7]. Aircraft Deliveries - A total of 1,692 aircraft are expected to be delivered in 2025, which is nearly 26% lower than previous estimates, with further downward revisions possible due to ongoing supply chain issues [8]. Regional Performance - North American carriers are projected to generate net profits of $12.7 billion in 2025, while European carriers are expected to see profits rise to $11.3 billion, driven by strong passenger demand [9]. - Net profits from Asia Pacific, Latin America, the Middle East, and Africa are expected to be $4.9 billion, $1.1 billion, $6.2 billion, and $0.2 billion, respectively [9]. Investment Opportunities - Companies such as Ryanair Holdings (RYAAY), Copa Holdings (CPA), and SkyWest (SKYW) are highlighted as potential investment opportunities due to their favorable earnings revisions and strong performance despite industry headwinds [2][11][12]. - Ryanair has a Zacks Rank 1 and has shown a 46.6% average earnings surprise over the past four quarters [15][16]. - Copa Holdings also holds a Zacks Rank 1 and has consistently beaten earnings estimates, with an average beat of 5.5% [18]. - SkyWest has a strong earnings surprise track record, surpassing estimates in each of the last four quarters with an average beat of 17.1% [20].